Malaria Vaccine: Pfs25-Pvs25
$1,178,399ZIAFY2014AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications, trials & patents
Paper 39127706Paper 37100721Paper 37061547Paper 36808125Paper 35915227Paper 35895391Paper 33824913Paper 33741942Paper 32709983Paper 30061051Paper 29982707Paper 29522056Paper 28722588Paper 28719292Paper 27432885Paper 26590432Paper 26428458Paper 26324116Paper 26003037Paper 24737801Paper 20434549Paper 20080619Paper 18612426Paper 17190797
Abstract
In order to develop a transmission blocking vaccine against P. vivax, LMIV started projects to chemically conjugate recombinant Pvs25 and Pvs230, orthologous proteins of transmission blocking vaccine candidates Pfs25 and Pfs230 being evaluated in the clinic by LMIV, to protein carriers. The monomeric proteins and conjugates thereof are being evaluated in animal studies for functional activity and immune enhancement, respectively and the antisera are being evaluated for transmission blocking activities in mosquitoes.
View original record on NIH RePORTER →